Related Experiment Video

Updated: Aug 24, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges

Amanda J Harvey1, Mark R Crompton

  • 1School of Biological Sciences, Royal Holloway University of London, Egham, Surrey TW20 0EX, UK.

Anti-Cancer Drugs
|April 13, 2004
PubMed

Insights

Brk tyrosine kinase is overexpressed in breast tumors and promotes cancer cell proliferation. Targeting Brk, potentially through protein-protein interactions, offers a promising avenue for novel breast cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Brk (also known as tyrosine kinase) is an intracellular protein tyrosine kinase.
  • Brk is overexpressed in most breast tumors but not in normal adult mammary gland tissues.
  • Brk promotes carcinoma cell proliferation, suggesting it's a viable target for cancer therapies.

Purpose of the Study:

  • To explore the role of Brk in breast cancer proliferation.
  • To evaluate Brk as a therapeutic target for novel cancer treatments.
  • To investigate potential therapeutic strategies, including kinase inhibition and protein-protein interaction inhibition.

Main Methods:

  • The study reviews existing research on Brk's function and overexpression in breast cancer.
  • It discusses the potential of targeting Brk's kinase activity and protein-protein interactions.
  • The abstract suggests further research into Brk's signaling pathways.

Main Results:

  • Brk overexpression is a hallmark of many breast tumors.
  • Brk actively promotes the proliferation of carcinoma cells.
  • Brk's role in proliferation is likely specific to cancer cells, not normal cells.

Conclusions:

  • Brk is a promising therapeutic target for breast cancer.
  • Both kinase inhibition and protein-protein interaction inhibition are potential strategies.
  • Further research into Brk signaling is crucial for developing effective drug discovery approaches.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...